Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc.（JNCE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · JNCE · 截至 2026年6月9日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
9
近12个月
买卖比
0.22
Buy/Sell (by trades)
整体情绪
Jounce Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
JNCE 季度内部人买卖趋势
JNCE 内幕交易卖出 · JNCE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
JNCE 高管卖出股份 · JNCE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 3, 2023 | Concentra Biosciences, LLC 10 percent owner | Other | 10,000 | $97.38M⚡ | Form 4 |
| May 3, 2023 | TANG KEVIN C Director | Other | 10,000 | $97.38M⚡ | Form 4 |
| May 3, 2023 | TANG KEVIN C Director | Other | 5,300,087 | $9.81M⚡ | Form 4 |
| May 3, 2023 | MURRAY RICHARD /CA/ Director | Other | 188,778 | $349K | Form 4 |
| May 3, 2023 | KARSEN PERRY A Director | Other | 5,000 | $9K | Form 4 |
| May 3, 2023 | Kamen Robert Director | Other | 33,875 | $63K | Form 4 |
| May 3, 2023 | Drapkin Kimberlee C President, CFO and Treasurer | Other | 25,751 | $48K | Form 4 |
| May 3, 2023 | Drapkin Kimberlee C President, CFO and Treasurer | Other | 40,267 | $74K | Form 4 |
| Apr 4, 2023 | MURRAY RICHARD /CA/ Director | Sale | 39,228 | $73K | Form 4 |
| Mar 14, 2023 | TANG KEVIN C 10 percent owner | Purchase | 20,286 | $21K | Form 4 |
| Mar 13, 2023 | TANG KEVIN C 10 percent owner | Purchase | 65,701 | $65K | Form 4 |
| Jan 9, 2023 | Trehu Elizabeth Chief Medical Officer | Sale | 4,159 | $5K | Form 4 |
| Jan 10, 2023 | Trehu Elizabeth Chief Medical Officer | Sale | 5,126 | $6K | Form 4 |
| Jan 9, 2023 | MURRAY RICHARD /CA/ CEO and President | Sale | 20,191 | $22K | Form 4 |
| Jan 10, 2023 | MURRAY RICHARD /CA/ CEO and President | Sale | 24,879 | $28K | Form 4 |
| Jan 9, 2023 | Drapkin Kimberlee C CFO and Treasurer | Sale | 6,315 | $7K | Form 4 |
| Jan 10, 2023 | Drapkin Kimberlee C CFO and Treasurer | Sale | 7,781 | $9K | Form 4 |
| Jan 9, 2023 | Cole Hugh M COO | Sale | 7,452 | $8K | Form 4 |
| Jan 10, 2023 | Cole Hugh M COO | Sale | 9,182 | $10K | Form 4 |
| Feb 1, 2022 | Cole Hugh M Chief Business Officer | Award | 42,500 | — | Form 4 |
| Feb 1, 2022 | Drapkin Kimberlee C CFO and Treasurer | Award | 27,500 | — | Form 4 |
| Feb 1, 2022 | MURRAY RICHARD /CA/ CEO and President · Director | Award | 87,500 | — | Form 4 |
| Feb 1, 2022 | Trehu Elizabeth Chief Medical Officer | Award | 27,500 | — | Form 4 |
| Jan 7, 2022 | Trehu Elizabeth Chief Medical Officer | Sale | 3,005 | $22K | Form 4 |
| Jan 10, 2022 | Trehu Elizabeth Chief Medical Officer | Sale | 5,378 | $36K | Form 4 |
Concentra Biosciences, LLC
10 percent owner
日期
May 3
股数
10,000
均价
$9737.70
总金额
$97.38M ⚡
Drapkin Kimberlee C
President, CFO and Treasurer
日期
May 3
股数
25,751
均价
$1.85
总金额
$48K
Drapkin Kimberlee C
President, CFO and Treasurer
日期
May 3
股数
40,267
均价
$1.85
总金额
$74K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 JNCE 内幕交易
JNCE 内幕交易
Jounce Therapeutics, Inc.（JNCE）内幕交易数据来源于公司内部人（包括JNCE）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。JNCE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Jounce Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
JNCE 内幕交易 · 5个问题Jounce Therapeutics, Inc.（JNCE）的内部人包括高管和董事，如JNCE等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026